Novel Dual Therapy: A Paradigm Shift in Anticoagulation in Patients of Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology

Background:

• Patients with atrial fibrillation (AF) on oral anticoagulation (OAC) often require percutaneous coronary intervention (PCI) due to coronary artery disease.
• Conventional triple therapy (Vitamin-K antagonist + dual antiplatelet therapy) prevents ischemia but increases bleeding risk and mortality.
• Novel oral anticoagulants (NOACs) offer reduced bleeding rates compared to VKAs.

Purpose of the Study:

• To review the shift from conventional triple therapy to novel dual therapy (NOAC + single antiplatelet therapy) in anticoagulated AF patients undergoing PCI.
• To discuss the benefits and strategies for mitigating bleeding risk while maintaining ischemic protection.

Main Methods:

• Review of existing literature and clinical trials on combination therapies in AF patients undergoing PCI.
• Analysis of bleeding and ischemic event rates associated with different antithrombotic strategies.
• Discussion of current guidelines and future perspectives.

Main Results:

• Novel dual therapy demonstrates a potential to reduce bleeding complications compared to traditional triple therapy.
• NOACs provide a favorable balance between efficacy and safety in this patient population.
• Balancing ischemic and bleeding risks remains a critical clinical consideration.

Conclusions:

• The paradigm is shifting towards NOAC-based dual therapy for AF patients undergoing PCI to minimize bleeding events.
• Further research and guideline updates are necessary to optimize antithrombotic strategies in this complex patient group.